OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi Sarcoma

September 27th 2021

Alice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.

Dr. Neal on the FDA Approval of Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

September 27th 2021

Joel Neal, MD, PhD, discusses the FDA accelerated approval of mobocertinib in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Reinmuth on the Rationale for Examining PROs With Tepotinib in METex14-Altered NSCLC

September 27th 2021

Niels Reinmuth, MD, PhD, discusses the rationale for a health utility analysis of tepotinib in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Dr. Cohen on CARTITUDE-2 Data With Cilta-Cel in Multiple Myeloma

September 27th 2021

Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Dr. Agarwal on the Design of the AMPLITUDE Trial in mCSPC

September 24th 2021

Neeraj Agarwal, MD, discusses the design of the ongoing phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Dr. Cohen on the Shortcomings of Trials Evaluating Cytoreductive Surgery and HIPEC in CRC

September 24th 2021

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Dr. Spira on the Impact of the PACIFIC-R Trial in Unresectable Stage III NSCLC

September 24th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the impact of the PACIFIC-R trial in patients with unresectable stage III non–small cell lung cancer.

Dr. Li on the Results of the DESTINY-Lung01 Trial in HER2+ Metastatic NSCLC

September 24th 2021

Bob T. Li, MD, PhD, MPH, discusses the results of the phase 2 DESTINY-Lung01 trial in HER2-positive metastatic non–small cell lung cancer.

Dr. Harbeck on Key Results From the WSG ADAPT-TP Trial in HER2+, HR+ Breast Cancer

September 24th 2021

Nadia Harbeck, MD, PhD, discusses the key results from the phase 2 WSG ADAPT-TP trial in patients with HER2-positive, hormone receptor–positive early-stage breast cancer.

Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC

September 24th 2021

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Dr. O’Malley on Balstilimab and Zalifrelimab in Recurrent/Metastatic Cervical Cancer

September 24th 2021

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

Dr. Mitri on Developments in HER2+ Breast Cancer

September 24th 2021

Zahi Mitri, MD, MS, discusses developments in the treatment of patients with HER2-positive breast cancer.

Dr. Sborov on Mitigating Monoclonal Antibody–Associated Toxicities in Multiple Myeloma

September 23rd 2021

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL

September 23rd 2021

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

September 23rd 2021

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

Dr. Kahl on a Potential Limitation of Frontline BTK Inhibitor Combos in MCL

September 22nd 2021

Brad S. Kahl, MD, discusses a potential limitation of frontline combination strategies with BTK inhibitors in mantle cell lymphoma.

Dr. Hubbard on the Barriers of Widely Implementing ctDNA ​Testing in CRC

September 22nd 2021

Joleen M. Hubbard, MD, discusses the barriers of implementing circulating tumor DNA into widespread clinical practice in colorectal cancer.

Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis

September 21st 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Dr. Cohen on Mitigation Strategies for CAR T-Cell Therapy in Multiple Myeloma

September 21st 2021

Adam D. Cohen, MD, discusses mitigation strategies that can be used for patients with relapsed/refractory multiple myeloma who are receiving the CAR T-cell therapy ciltacabtagene autoleucel.

Dr. Raghav on Regorafenib Dose Optimization in CRC

September 21st 2021

Kanwal Raghav, MBBS, MD, discusses optimal dosing strategies for regorafenib in patients with colorectal cancer.

NEXT PAGE
PREVIOUS PAGE